1 sri ramachandra medical college and research institute, chennai, India 2 sri ramachandra university, chennai, India 3 Sri Ramachandra Medical College & Research Institute, Chennai, India 4 SRI RAMACHANDRA MEDICAL COLLEGE AND RESEARCH INSTITUTE, SRI RAMACHANDRA UNIVERSITY, Chennai, India 5 Sri Ramachandra University, Cheannai, India Background: According to WHO, India has around 40 million chronic HBV carriers. This study was carried out with objectives; profiling of viral markers in HBV carriers with viral load, correlation of ALT levels, HBe Ag status with their viral load, to determine the mutation and response to antiviral therapy in treated and treatment naïve individuals.
Methods & Materials: DNA was extracted from plasma by Qiagen DNA blood mini kit (Qiagen, Germany). HBV viral load was estimated by Artus HBV real time PCR kit (Qiagen, Germany) in ABI HT fast real time PCR platform (Applied Biosystems, USA). Randomly 27 high viral load samples were chosen and polymerase gene was amplified using specific primers by Platinum Taq DNA polymerase kit (Invitrogen, USA) and sanger sequencing (Big Dye terminator kit, ABI, USA) was performed to identify the drug resistance mutations and genotyping. Mutational analysis was done by HBV geno2pheno software.
Results: Among 1129 samples tested for viral loads, 26% (n=295) had high viral load (Median HBV viral load is 7×10 5 IU/ml, range: 2×10 3 IU/ml to 4×10 7 IU/ml), of which 113 samples had viral load between 2000 IU/ml -20,000 IU/ml and 182 had more than 20,000 IU/ml. 31% had detectable viral load below 2000 IU/ml.. HBe Ag status were checked for these patients, HBe Ag status were known for 545 patients, 26% (n=141) were found positive for HBe Ag, 13.7% had high viral load with HBe Ag negative. HBe Ag positivity was positively correlated with the high viral load with p<0.001 (STATA II software). Elevated ALT levels were seen in patients with high viral load and the correlation was significant with p<0.001. Among 27 individuals, mutation rtM204V along with rtL180M was seen in one treated individual and a compensatory mutation was observed in other treatment naive individual.
Conclusion: Periodic monitoring of these patients for factors like viral load, HBe Ag status and ALT level will enable the clinician to initiate appropriate therapy at the right time to obtain sustained virological response.
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